References

Print
Related Pages
HIV Prevention in the United States: Mobilizing to End the Epidemic

References

  1. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2014–2018. HIV Surveillance Supplemental Report 2020;25(No. 1). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2020. Accessed January 13, 2021.
  2. Vital signs: HIV and injection drug use. 2016 Dec. https://www.cdc.gov/vitalsigns/pdf/2016-12-vitalsigns.pdf.
  3. Hall IH, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008 Aug 6;300(5):520–529.
  4. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  5. Estimated HIV incidence and prevalence in the United States, 2014-2018
  6. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  7. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  8. S. Census Bureau. National Population by Characteristics: 2010-2019. https://www.census.gov/data/tables/time-series/demo/popest/2010s-national-detail.html. Accessed November 30, 2020.
  9. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  10. Sexual Orientation Information Statistics. Sexual Orientation and Health among U.S. Adults: National Health Interview Survey, 2018. https://www.cdc.gov/nchs/data/nhis/sexual_orientation/ASI_2018_STWebsite_Tables-508.pdf. Accessed January 13, 2021.
  11. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  12. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  13. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018. HIV Surveillance Supplemental Report 2020;25(No. 2). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2020. Accessed January 13, 2021.
  14. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  15. Becasen JS, Denard CL, Mullins MM, et al. Estimating the Prevalence of HIV and Sexual Behaviors Among the US Transgender Population: A Systematic Review and Meta-Analysis, 2006-2017. Am J Public Health. 2018 Nov 29:e1-e8.
  16. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  17. S. Census Bureau. Evaluation Estimates. Annual Estimates of the Resident Population for the United States, Regions, States, and the District of Columbia: April 1, 2010 to July 1, 2020. https://www.census.gov/programs-surveys/popest/technical-documentation/research/evaluation-estimates.html. Accessed January 13, 2021.
  18. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  19. NCHHSTP AtlasPlus database.
  20. Custom data analysis, National HIV Surveillance System data reported to CDC through December 2019.
  21. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018.
  22. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  23. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018.
  24. Estimated HIV incidence and prevalence in the United States, 2014-2018.
  25. Pitasi MA, Delaney KP, Brooks JT, et al. HIV Testing in 50 Local Jurisdictions Accounting for the Majority of New HIV Diagnoses and Seven States with Disproportionate Occurrence of HIV in Rural Areas, 2016–2017. MMWR Morb Mortal Wkly Rep. 2019;68:561–567.
  26. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR14);1-17.
  27. DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV Screening of Gay, Bisexual, and Other Men Who Have Sex with Men — United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66:830–832.
  28. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet. 2014;14:820-9.
  29. Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016 Jan;176(1):75-84.
  30. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016 Jan 2;387(10013):53-60.
  31. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601-3.
  32. Marcus JL, Hurley LB, Nguyen DP, et al. Redefining Human Immunodeficiency Virus (HIV) preexposure prophylaxis failures. Clin Infect Dis. 2017;65(10):1768-9.
  33. Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014 Feb;43(1):235-48.
  34. Bernard CL, Owens DK, Goldhaber-Fiebert JD, et al. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis. PLoS Med. 2017 May 24;14(5):e1002312.
  35. Hagan H, McGough JP, Thiede H, et al. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000 Oct;19(3):247-52.
  36. Harris NS, Johnson AS, Huang YA, et al. Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018. MMWR Morb Mortal Wkly Rep. 2019; 68(48):1117-1123.
  37. Finlayson T, Cha S, Xia M, et al. Changes in HIV Preexposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men — 20 Urban Areas, 2014 and 2017. MMWR Morb Mortal Wkly Rep. 2019;68(27):597–603.
  38. Zarwell M, John SA, Westmoreland D, et al. PrEP Uptake and Discontinuation Among a U.S. National Sample of Transgender Men and Women. AIDS Behav. 2020 Oct 15. Online ahead of print.
  39. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.
  40. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016 Sep 1;375(9):830-9.
  41. Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016 Jul 12;316(2):171-81.
  42. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019 Jun 15;393(10189):2428-2438.
  43. Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018 Aug;5(8):e438-e447. [published correction appears in Lancet HIV. 2018 Oct;5(10):e545].
  44. Bernstein KT, Marcus JL, Nieri G, et al. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):537-43.
  45. Charania MR, Crepaz N, Guenther-Gray C, et al. Efficacy of Structural-Level Condom Distribution Interventions: A Meta-Analysis of U.S. and International Studies, 1998–2007. AIDS Behav. 2011;15(7):1283–1297.
  46. Custom data analysis, National HIV Surveillance System data reported to CDC through December 2019.
Contents
Top of Page